Alexion preclinical data

The New Haven, Conn., company announced a new class of recombinant therapeutics called Apogens that it said can selectively eliminate T cells causing autoimmune diseases.

At the Advances in the Understanding and Treatment of Multiple Sclerosis conference in Cambridge, Mass., data from animal testing showed that the first such compound, MP4, ameliorated disease in an animal model of multiple sclerosis. The agent prevented disease when given to mice with experimental allergic encephalomyelitis induced by either myelin basic protein or proteolipid protein. ...